GlobeNewswire by notified

HMNC Brain Health Expands International Patent Portfolio with Two Stress-axis Related Substances for Major Depressive Disorder

Share

In-Licensing arrangement with the renowned Max Planck Society, extends patent protection for clinical research and strengthens Nelivabon and Cortibon developmental projects

The Company has also established an office in the United States, furthering global expansion strategy

MUNICH, Germany, Jan. 25, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health, (“HMNC” or the “company”), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced that it has expanded its international patent portfolio in the field of psychiatric therapy with two patent families claiming substances for treating stress-axis related Major Depressive Disorder. These license agreements are part of a broader collaboration with the renowned Max-Planck-Society, comprising biomarker patent claims and therapeutic patent claims covering markets in Europe, the U.S., and now Asia, in particular Japan.

Utilizing a more personalized approach to discovering new drugs in psychiatry, the two targeted stress hormone therapies are promising patent candidates – Corticotropin-Releasing Hormone Receptor 1 (CRHR1) antagonists and vasopressin1B – receptor (V1BR) antagonists. Because only a limited proportion of patients with stress-related depression have persistently elevated levels of CRH or vasopressin, by tailoring therapies according to an individual’s biosignature through this targeted approach, some patients could better control the triggers for the production of a stress hormone.

Benedikt von Braunmühl, CEO at HMNC Brain Health, said:
“This is yet another example of our effective scientific collaborative initiatives, based on more than 30 years of research in depression and anxiety disorders. By strengthening the strategic intellectual property protection of our assets, we are further developing our patent portfolio internationally, with newly signed licenses and the assistance of Dr. Christian Kilger, a Patent Attorney from CH KILGER in Berlin. Dr. Kilger has led numerous companies successfully through complex patent oppositions, patent litigations, and IPOs in the international biotech arena and will help us to fully realize the therapeutic and commercial potential of our compounds and develop them globally for the patients in need as well as for our investors.”

The first patent in-licenses the granted Japanese patent JP 6309511 B2, a V1b antagonist – which is being developed within the Company’s subsidiary Nelivabon Project for use in the treatment of patients showing an elevated Arginine Vasopressin (AVP) level.

The second patent family relates to the CRHR1 antagonist project for use in the treatment of patients having Corticotropin-Releasing Hormone (CRH) overactivity. EP 2 841 068 B1 was granted in 2018 and will expire in 2033. The filing of a supplementary protection certificate could further extend the patent term. The Company also currently has pending patent applications in the United States and Japan. These therapeutic patent claims stand alongside two further patent families covering CRHR1 antagonist patient response (proprietary biomarkers).

HMNC Brain Health’s Chief Clinical Development Officer, Dr. Hans Eriksson, added: “The extended patent protection supports us in pursuing highest quality clinical research as we work to transform therapy of neuropsychiatric disorders. We will put all our effort in developing these promising compounds into highly efficient medications and improve the lives of many patients suffering from Major Depressive Disorder.”

In addition, HMNC Brain Health announced that it has established an office in the United States as the next step in furthering its international expansion strategy. This follows the recent appointment of Nir Naor, who is based in the United States, as HMNC Brain Health’s new Chief Financial Officer.

“We are entering an important phase of growth for the Company and establishing a presence in the United States is a key milestone in our strategy of operational expansion and global capital markets engagement,” said Mr. von Braunmühl.

About HMNC Brain Health
HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates. The company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). The company has operations in both the US and Germany and is backed by a renowned global venture capital firm, several family offices and a strategic healthcare investor. The company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

About the Nelivabon Project
HMNC Brain Health’s Nelivabon project comprises the Phase-II-ready compound nelivaptan and a matching molecular diagnostic test targeting the 30% of Major Depressive Disorder (MDD) related to a dysfunction in the human body’s stress system (HPA-axis). The neuropeptide vasopressin coordinates hormonal and behavioral adaptation to stress. Repeated stressors cause an elevated activity of vasopressin in the brain, potentially resulting in an increase of anxiety and a major depressive episode. BH-200 is an antagonist at the vasopressin V1b receptor, expected to be able to treat this dysfunction. The clinical development is combined with a predictive companion diagnostic, which identifies depressed patients with an underlying dysfunction of the HPA-axis. Once clinically validated in conjunction with its predictive companion diagnostic, the Nelivabon project could represent a highly efficient treatment for those patients suffering stress-axis-related MDD. The project is entering a Phase-II proof-of concept study in 2022.

About the Cortibon Project
Within the Cortibon project, HMNC Brain Health develops the compound E2009, a corticotropin-releasing hormone (CRH) receptor 1 antagonist, in-licensed from Eisai, together with a companion diagnostic. The neuropeptide corticotropin-releasing hormone coordinates hormonal and behavioral adaptation to stress. In about one third of patients with depression, CRH is believed to be involved in the development of the disorder. CRH antagonists thus have the potential to improve the depressive symptoms. So far, it has not been possible to identify the patients in which elevated CRH in the brain is the cause of depression. As a result, CRHR1 antagonists have not yet entered the market. HMNC Brain Health has developed and clinically validated a molecular laboratory test that allows to select the subset of depressed individuals with a disturbance in their stress axis system and thus indicates which patients with depression will respond well to a CRH blocker and which will not.

Media Contacts
Alexander Schmidt (Europe)
+49 151 22 99 39 765
alexander.schmidt@gaulyadvisors.com

Anne Donohoe (U.S.)
+1 212-896-1265
hmnc@kcsa.com

Investor Contact (U.S.)
Tim Regan
+1 347-487-6788
tregan@kcsa.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nextensa NV/SA : Shares repurchase26.5.2022 17:40:00 CEST | Press release

PRESS RELEASE REGULATED INFORMATION Brussels, 26 May 2022 – 5.40 PM CEST Nextensa NV/SA : Shares repurchase In accordance with article 8:4 of the Royal Decree of 29 April 2019 in execution of the Belgian Code of Companies and Associations, Nextensa announces that in the period between May 19, 2022 and May 25, 2022 included it has repurchased 1,889 treasury shares on Euronext Brussels as part of its announced share buy-back program1. The shares were repurchased at an average price (rounded) of € 68.00 per share. This share repurchase transaction was carried out to cover the purchase plans for the benefit of the executive management of Nextensa, and this within the limits set down in the (renewed) share repurchase authorization as granted by the extraordinary general meeting of shareholders on 19 July 2021. Detailed operations per day DateNumber of sharesAverage price (€)Minimum price (€)Maximum price (€)Total price (€)19/05/202245067.8667.7067.9030,535.0020/05/202245068.4868.4068.9030,8

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons26.5.2022 15:00:33 CEST | Press release

26 May 2022 VOLTA FINANCE LIMITED (VTA / VTAS) Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons On 24 May 2022, Mr Paul Meader, Director and Chairman of the Board of the Company, transferred 3,130 shares in the Company to his wife, Sarah Kingwell. Following this transaction the total interests in the Company of Mr Meader (and his Closely Associated Persons) remain unchanged at 48,175 shares, representing 0.13% of the issued shares in the Company. The below notification, made in accordance with the requirements of article 19.3 of the EU Market Abuse Regulation, gives further details: 1 Details of the person discharging managerial responsibilities / person closely associated a) Name 1) Paul Meader 2) Sarah Kingwell 2 Reason for the notification a) Position/status 1) Director and Chairman 2) PCA b) Initial notification /Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platfor

Mandalay Resources Corporation tillkännager resultatet av årsstämman26.5.2022 14:41:34 CEST | Pressemelding

TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) har nöjet att tillkännage resultaten från årsstämman (”mötet”) som hölls virtuellt idag. Alla resolutioner som presenterades vid mötet godkändes av aktieägarna och röstningen som skedde genom fullmakt motsvarade 67,63 % av de totalt utestående aktierna på avstämningsdagen. Val av styrelseledamöter Antalet styrelseledamöter var oförändrat med sju ledamöter och var och en av de sju nominerade som fanns listade i bolagsledningens informationsutskick från den 14 april 2022 återvaldes till bolagsstyrelsen. Abraham Jonker fortsätter som oberoende samordnande ledamot och Bradford Mills fortsätter som ordförande. Resultaten av rösterna genom ombud anges nedan. ResolutionVotes Cast by Proxy For% ForVotes Cast by Proxy Withheld% WithheldBradford A. Mills61,552,12099.95329,1930.047Abraham Jonker61,551,31399.95130,0000.049Amy Freedman61,547,53899.94533,7750.055Dominic Duff

Interim results for the period ended March 31, 202226.5.2022 13:30:47 CEST | Press release

Golar LNG Limited ("Golar" or "the Company") reports Q1 2022 ("Q1") Net income of $345.2 million.Adjusted EBITDA1 of $93.4 million for the quarter inclusive of FLNG Hilli, Golar Arctic and Golar Tundra but excluding the 8 TFDE vessels and management companies sold to Cool Company Ltd. ("CoolCo"). Sold 6.2 million New Fortress Energy Inc. ("NFE") shares in Q2 2022 ("Q2") realizing net cash proceeds of $253 million. Golar now owns 12.4 millionNFE shares following the sale.Q1 Total Golar Cash and Listed Securities1 position increased by $0.4 billion to $1.3 billion. Golar's share of Contractual Debt1 decreased by $0.5 billion to $1.7 billion in Q1 and a further $0.5 billion in Q2 after sale of remaining carriers to CoolCo in April.Agreed to sell the steam turbine carrier Golar Arctic as a converted FSRU to Italy's Snam for 269 million Euros ($288 million). Strong progress made on opportunities for FSRU Golar Tundra and on pipeline of FLNG projects. Shipping spin-off: A key focus for Q1 wa

Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery26.5.2022 13:30:00 CEST | Press release

– Company announces rebranding to Dante Genomics to reflect its broader global efforts – NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases. Since the company’s foundation, Dante has invested in a robust R&D program with the goal to create end-to-end solutions from diagnosis to therapy. Dante’s program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante’s pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co-development to achieve validation and partner externally on clinical trials and commercialization. “Personalized medicine needs personalized data, a